620113-73-7
Chemical Structure
CCG-63808
- CAS No.: 620113-73-7
- Formula:C25H15FN4O2S
- Molecular Weight:454.48
IUPAC Name: (E)-2-(benzo[d]thiazol-2-yl)-3-(2-(4-fluorophenoxy)-9-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)acrylonitrile
InChIKey: IPZHFKHGSYRBNT-DTQAZKPQSA-N
SMILES: N#C/C(C1=NC2=CC=CC=C2S1)=C\C3=C(N=C4C(C)=CC=CN4C3=O)OC5=CC=C(C=C5)F
Biological Activity: CCG-63808 is a selective, reversible RGS4 inhibitor with an IC50 of 10 μM for the Gαo-RGS4 interaction. CCG-63808 enhances the contractile response of lymphatic smooth muscle and potentiates agonist-mediated thoracic duct contraction. CCG-63808 can be used in research related to neuropathic pain and hypertension[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CCG-63808 | 98.0% | CCG-63808 is a selective, reversible RGS4 inhibitor with an IC50 of 10 μM for the Gαo-RGS4 interaction. CCG-63808 enhances the contractile response of lymphatic smooth muscle and potentiates agonist-mediated thoracic duct contraction. CCG-63808 can be used in research related to neuropathic pain and hypertension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Blazer LL, et al. Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. Mol Pharmacol. 2010;78(3):524-533. [Content Brief]
- [2]. Mukohda M, et al. Hypertension is linked to enhanced lymphatic contractile response via RGS16/RhoA/ROCK pathway. Am J Physiol Heart Circ Physiol. 2022;323(6):H1118-H1129. [Content Brief]
